Skip to Content

EyePoint Pharmaceuticals Inc EYPT

Morningstar Rating
$28.00 +0.79 (2.90%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

EYPT is trading at a 29% discount.
Price
$28.00
Fair Value
$68.19
Uncertainty
Extreme
1-Star Price
$388.79
5-Star Price
$55.59
Economic Moat
Mcdc
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if EYPT is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$27.21
Day Range
$27.2728.79
52-Week Range
$2.2130.99
Bid/Ask
$27.30 / $29.25
Market Cap
$1.37 Bil
Volume/Avg
899,679 / 1.9 Mil

Key Statistics

Price/Earnings (Normalized)
Price/Sales
24.82
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Core
Total Number of Employees
144

Comparables

Valuation

Metric
EYPT
TARS
EWTX
Price/Earnings (Normalized)
Price/Book Value
16.876.423.69
Price/Sales
24.8262.23
Price/Cash Flow
Price/Earnings
EYPT
TARS
EWTX

Financial Strength

Metric
EYPT
TARS
EWTX
Quick Ratio
2.146.6418.98
Current Ratio
2.356.9319.50
Interest Coverage
−51.18−44.34
Quick Ratio
EYPT
TARS
EWTX

Profitability

Metric
EYPT
TARS
EWTX
Return on Assets (Normalized)
−37.19%−50.11%−24.36%
Return on Equity (Normalized)
−77.61%−62.96%−25.87%
Return on Invested Capital (Normalized)
−61.03%−58.53%−29.82%
Return on Assets
EYPT
TARS
EWTX
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRKqs$550.4 Bil
VRTX
Vertex Pharmaceuticals IncXprwq$111.8 Bil
REGN
Regeneron Pharmaceuticals IncQhsnpd$107.9 Bil
MRNA
Moderna IncPvst$36.3 Bil
ARGX
argenx SE ADRHsbfc$23.0 Bil
BNTX
BioNTech SE ADRWjvcj$21.6 Bil
ALNY
Alnylam Pharmaceuticals IncXthdsxg$19.2 Bil
BMRN
Biomarin Pharmaceutical IncMcjyh$16.4 Bil
RPRX
Royalty Pharma PLC Class AShqqltp$13.4 Bil
INCY
Incyte CorpChwvr$13.3 Bil

Sponsor Center